FDA grants breakthrough therapy status for Merck’s lung cancer drug Keytruda
Keytruda is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. The breakthrough status for Keytruda is to treat these patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.